Predicine Submits First PMA Module to FDA for Bladder Cancer Companion Diagnostic
The urine-based NGS assay received Breakthrough Device Designation in 2022 and targets genomic alterations in cancer-associated genes.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
